We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    lisa hudgins
Previous Study | Return to List | Next Study

Fructose-induced Hepatic De Novo Lipogenesis in Adolescents With Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03567837
Recruitment Status : Recruiting
First Posted : June 26, 2018
Last Update Posted : March 17, 2023
Weill Medical College of Cornell University
University of Missouri-Columbia
Information provided by (Responsible Party):
The Rogosin Institute

Brief Summary:

In the U.S., dietary fructose has increased in parallel with the increase in obesity and may promote the development of diabetes and other chronic diseases. The largest source of dietary fructose is sweetened beverages that are consumed by adolescents more than any other age group.

This protocol will compare the rates of hepatic de novo lipogenesis (DNL), a process in the liver that changes sugar into fat, in two groups of obese adolescents - one with prediabetes and the other, metabolically healthy. Blood will be sampled before and hourly for 3 hours after the consumption of a fructose-containing beverage. We hypothesize that the pre-diabetic group will show greater DNL in response to fructose. This would support other evidence that increased fructose-induced hepatic DNL is an early mechanism linking dietary sugar to the adverse metabolic sequelae of obesity, including diabetes, fatty liver, dyslipidemia and coronary disease.

Condition or disease Intervention/treatment Phase
Adolescent Obesity Other: Fructose + Glucose Beverage Not Applicable

Detailed Description:

Hypothesis: Hepatic DNL in response to the ingestion of fructose:glucose 1:1 is significantly greater in adolescents with obesity and prediabetes compared to adolescents with obesity who are metabolically healthy.

Thirty obese adolescents, ages 12-21 years, will be recruited to each of two groups: 1) prediabetes (n=15) and 2) metabolically healthy (n=15). An attempt will be made to achieve similar age, sex and BMI distributions in the two groups.

Visit 1- Screening: Eligible subjects will be enrolled after Informed consent/assent are obtained by a physician investigator. The medical history will be reviewed and a physical exam performed, including an assessment of pubertal status. Blood will be sampled after at least a 12 hour fast (except water) for complete blood count, serum glutamate pyruvate, glucose, HbA1C, and lipid panel, if not previously documented in the medical record within three months of the screening visit. These tests may be done without fasting, but if the glucose or lipid results are not normal, these two tests must be repeated after fasting.

Visit 2 - Sugar Challenge Test with Blood Sampling: Within three months of the screening visit, eligible participants will return after at least a 12 hour fast (except water). General health, family history and recent diet will be reviewed. The height, weight, waist circumference at the umbilicus, and blood pressure will be recorded. A urine sample will be obtained for microalbuminuria. After placement of an intravenous catheter and withdrawal of the baseline blood samples, participants will drink a sweet beverage prepared by a dietician (fructose:glucose 1:1, 3g/kg, in water). Blood sampling will continue every hour for three hours( ~12 mL per time point).

Percent body fat will be measured by bioimpedance. The percent body fat will be calculated by computer software with prediction equations validated in the pediatric and adult age ranges.

Plasma samples will be obtained at 4 time points (0, 1, 2 and 3 hours), the fatty acid composition of plasma very low density lipoprotein triglyceride (VLDL TG), including %palmitate (16:0), will be measured. A lipid panel and VLDL triglycerides and apolipoprotein B levels will also be measured at each time point. Other assays to be performed include insulin and and glucose, HbA1C and high sensitivity C reactive protein (hsCRP, a marker of inflammation). The urine sample will be assayed for microalbuminuria (albumin/creatinine >30 mg/g).

An interim analysis of the primary endpoint (increase in VLDL TG %16:0) will be performed in the first three subjects of each group to determine whether the dose of sugar and sampling duration of 3 hours are sufficient to produce a measurable increase in VLDL TG %16:0.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Fructose-induced Hepatic De Novo Lipogenesis in Adolescents With Obesity
Actual Study Start Date : August 13, 2018
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Fructose

Arm Intervention/treatment
Active Comparator: Obese Metabolically Healthy
Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
Other: Fructose + Glucose Beverage
The intervention is an oral sugar challenge with blood sampling over three hours.

Experimental: Obese Pre-diabetes
Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
Other: Fructose + Glucose Beverage
The intervention is an oral sugar challenge with blood sampling over three hours.

Primary Outcome Measures :
  1. Increase in VLDL TG palmitate [ Time Frame: Three hours ]

    In the 2 study groups: a comparison of the increase in VLDL TG palmitate over 3 hours after ingestion of a beverage made with fructose and glucose.

    after an oral challenge of fructose+glucose

Secondary Outcome Measures :
  1. Correlation of the increase in VLDL TG palmitate and markers of carbohydrate and fatty acid metabolism [ Time Frame: Three hours ]

    In the two study groups: a comparison of other markers of carbohydrate and fatty acid metabolism (i.e. VLDL and total TG, cholesterol, apolipoprotein B, insulin, and glucose) before and after the oral sugar challenge.

    2) To correlate these markers with the increase in VLDL TG %16:0.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age: 12-21 years old.
  2. BMI percentile >95th and <140th percentile of the 95th, maximum weight 110 kg.
  3. Group 1: HbA1C <5.7% and no history of fasting hyperglycemia (glucose greater or equal to100 mg/dL and/or HbA1C greater or equal to 5.7%), sustained hypertension (>95th percentile) or abnormal lipids (LDL cholesterol <130 mg/dL, TG <130 mg/dL, HDL-C >40 mg/dL).

    Group 2: HbA1C greater or equal to 5.7 to 6.49%

  4. Pubertal or post- pubertal stage (pre-pubertal excluded).
  5. Willing and able to stop fish oil, fiber supplement, other non-prescribed vitamins/supplements for 1 week prior to study visit.
  6. Willing to not drink alcohol for at least 48 hours before the study visit.
  7. Willing to refrain from vigorous exercise the day before the study visit.

Exclusion Criteria:

  1. Diabetes (fasting blood glucose greater or equal to126 mg/dL, and/or HbA1C >6.5% and/or history of a 2 hour oral glucose tolerance test (OGTT) >200 mg/dL).
  2. Triglycerides >500 mg/dL, LDL cholesterol >160 mg/dL.
  3. Medications affecting lipid or glucose metabolism, including hormonal contraceptives.
  4. Liver disease or intestinal dysfunction. Serum glutamate oxaloacetate and/or serum glutamate pyruvate < 2x upper limit normal is permitted if there is no diagnosis of liver disease by a gastroenterologist.
  5. Weight loss >10% in past 6 months.
  6. Cigarette smoking.
  7. Alcohol or drug abuse.
  8. Systemic illness, including polycystic ovary disease and acute infections within two weeks of study visits.
  9. Anemia.
  10. Pregnancy or breast feeding.
  11. Psychiatric illness.
  12. Extreme diet or level of physical activity.
  13. Fructose intolerance.
  14. Implanted electronic devices (bioimpedance measurement).
  15. Any other condition, which in the opinion of the principal investigator, should prohibit participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03567837

Layout table for location contacts
Contact: Lisa Hudgins, MD 646-317-0805 lih2013@nyp.org

Layout table for location information
United States, New York
Weill Cornell Medicial College Recruiting
New York, New York, United States, 10065
Contact: Lisa Hudgins, MD         
Sponsors and Collaborators
The Rogosin Institute
Weill Medical College of Cornell University
University of Missouri-Columbia
Layout table for investigator information
Principal Investigator: Lisa Hudgins, MD The Rogosin Institute
Layout table for additonal information
Responsible Party: The Rogosin Institute
ClinicalTrials.gov Identifier: NCT03567837    
Other Study ID Numbers: 180401921
First Posted: June 26, 2018    Key Record Dates
Last Update Posted: March 17, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pediatric Obesity
Nutrition Disorders
Body Weight